Search Results
Oct 02, 2025, 08:30 ET Celltrion launches AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in the United States
immunogenicity of CT-P47 compared to reference tocilizumab, AVTOZMA received approval from the U.S. Food and Drug Administration (FDA) and European Commission (EC) in January and February 2025, respectively. In July 2025, the FDA approved an additional indication for the intravenous (IV) formulation of AVTOZMA
More news about: Celltrion
Oct 02, 2025, 08:08 ET Eisai Highlights Breadth of Oncology Research at ESMO 2025, Featuring 5-Year Survival Data from Study 309/KEYNOTE-775
adjustment is recommended for patients with DTC, RCC, or EC and mild or moderate hepatic impairment. LENVIMA concentrations may increase in patients with DTC, RCC, or EC and severe hepatic impairment. Reduce the dose for patients with DTC, RCC, or EC and severe hepatic impairment. LENVIMA
More news about: Eisai Inc.
Sep 30, 2025, 17:34 ET Music Tourism Market to Reach USD 400.5 Billion by 2032, Growing At An 18.6% CAGR - Credence Research
Contact Us Credence Research Europe LTD128 City Road, London,EC1V 2NX, UNITED KINGDOMEurope - +44 7809 866 263North America - +1 304 308 1216Australia - +61 4192 46279Asia Pacific -
More news about: Credence Research Inc.
Sep 25, 2025, 18:39 ET Lilly's Kisunla (donanemab) receives marketing authorization by European Commission for the treatment of early symptomatic Alzheimer's disease
Sept. 25, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Commission (EC) has granted marketing authorization for Kisunla (donanemab) for the treatment of early symptomatic Alzheimer's disease (AD), in adults with mild cognitive
More news about: Eli Lilly and Company
Sep 25, 2025, 09:35 ET Wiv.ai Achieves AWS Generative AI Competency for FinOps Automation
proficiency and customer success in building generative AI solutions using services such as Amazon Bedrock, Amazon SageMaker, and Amazon EC2. Anyone can spin up a GenAI product. Building one that truly works at scale and is enterprise-ready is something else entirely," said
More news about: Wiv.ai
Sep 25, 2025, 09:15 ET Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
https://www.advisory.com/daily-briefing/2025/08/25/urgent-care-ecLogo:
More news about: USA News Group
Sep 23, 2025, 13:58 ET Credence Research expands global presence with a new European office in London
Europe with the launch of Credence Research Europe Ltd., located at 128 City Road, London, EC1V 2NX, United Kingdom. The new office will serve as a strategic hub to address the growing European demand and to provide
More news about: Credence Research Inc.
Sep 23, 2025, 07:29 ET Sweden, the world's first travel destination on prescription
Imagery https://visitsweden.qbank.se/mb/?h=63b119a75da85e1326ba45ec0147409c Video - https://www.youtube.com/watch?v=hqo3PZwOZhkPhoto
More news about: Visit Sweden AB
Sep 23, 2025, 04:57 ET Kelun-Biotech to Present Results from Multiple Clinical Studies at the 2025 ESMO Congress
9:00 AM to 5:00 PM local time Title: Sacituzumab tirumotecan (Sac-TMT) Monotherapy in Advanced/Metastatic Endometrial Carcinoma (EC): Results from a Phase 1/2 Study (MK-2870-001/KL264-01)Presentation Type: PosterPresentation #: 1111PDate
More news about: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Sep 23, 2025, 02:29 ET Sweden, the world's first travel destination on prescription
Imagery https://visitsweden.qbank.se/mb/?h=63b119a75da85e1326ba45ec0147409c Video - https://www.youtube.com/watch?v=hqo3PZwOZhkPhoto
More news about: Visit Sweden AB
Sep 23, 2025, 01:29 ET Suecia, el primer destino turístico del mundo con receta médica
Imágenes https://visitsweden.qbank.se/mb/?h=63b119a75da85e1326ba45ec0147409c Video - https://www.youtube.com/watch?v=hqo3PZwOZhkFoto
More news about: Visit Sweden AB
Sep 23, 2025, 01:29 ET Schweden, das erste Land auf Rezept
Pressebilder: https://visitsweden.qbank.se/mb/?h=63b119a75da85e1326ba45ec0147409c Quelle: Survey, June/July 2025, Visit Sweden / YouGov Video -
More news about: Visit Sweden AB
Sep 23, 2025, 01:29 ET La Suède - premier pays au monde disponible sur prescription médicale
médicale : https://visitsweden.qbank.se/mb/?h=63b119a75da85e1326ba45ec0147409c Vidéo -
More news about: Visit Sweden AB
Sep 22, 2025, 18:29 ET スウェーデン、世界初の処方箋による旅行先に
画像 https://visitsweden.qbank.se/mb/?h=63b119a75da85e1326ba45ec0147409c 動画 -https://www.youtube.com/watch?v=hqo3PZwOZhk写真
More news about: Visit Sweden AB
Sep 22, 2025, 17:31 ET Prurigo Nodularis market to exhibit growth at a CAGR of 23.2% (2020-2034), driven by strong uptake of DUPIXENT, recent approval of NEMLUVIO, promising JAK and OX40 inhibitors in the Pipeline, along with rising prevalence | DelveInsight
received marketing authorization for NEMLUVIO from both the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Commission (EC) for the SC treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy.Leading companies
More news about: DelveInsight Business Research, LLP
Sep 22, 2025, 14:10 ET Omio e České dráhy annunciano una partnership strategica che amplia le opzioni di viaggio in treno attraverso l'Europa
partnership. La collaborazione offre ai viaggiatori Omio l'opportunità di prenotare i servizi di České dráhy, inclusi i treni Regio, InterCity (IC) ed EuroCity (EC) a lunga percorrenza, oltre alle opzioni ad alta velocità (Railjet/Comfortjet). L'aggiunta dell'ampio inventario di Czech dráhy da questo settembre rafforza
More news about: Omio
Sep 22, 2025, 14:06 ET Omio y České dráhy anuncian una alianza estratégica que amplía las opciones de viaje en tren a través de Europa
viajeros de Omio podrán reservar directamente los servicios de České dráhy, que incluyen rutas de larga distancia Regio, InterCity (IC) y EuroCity (EC), así como trenes de alta velocidad (Railjet/Comfortjet). La integración del amplio inventario de České dráhy refuerza la posición de Omio como referente
More news about: Omio
Sep 22, 2025, 13:24 ET Omio and České dráhy announce strategic partnership, elevating European cross-border train travel options
partnership. This collaboration creates the opportunity for Omio travellers to book České dráhy services, including Regio, InterCity (IC) and EuroCity (EC) long-distance routes, plus high-speed train options (Railjet/Comfortjet). The addition of České dráhy's comprehensive inventory from this September
More news about: Omio
Sep 22, 2025, 08:05 ET European Commission Approves Servier's VORANIGO® (vorasidenib) as the First Targeted Therapy for Grade 2 IDH-Mutant Glioma in the EU
2025 /PRNewswire/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that the European Commission (EC) has approved VORANIGO® (vorasidenib) for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate
More news about: Servier Pharmaceuticals
Sep 19, 2025, 08:30 ET TECVAYLI® and DARZALEX FASPRO®-based induction treatment demonstrates promising rates and depths of response in transplant-eligible patients with newly diagnosed multiple myeloma
anti-CD38 antibody.3 Since FDA approval, more than 15,900 patients have been treated worldwide with TECVAYLI®. The European Commission (EC) granted TECVAYLI®
More news about: Johnson & Johnson
Sep 18, 2025, 11:24 ET Audi Debuts First E5 Sportback with Ambilight's Electrochromic Smart Dimming Sunroof
Ferrari's Superamerica, EC dimming was once a niche innovation. Since 2017, Ambilight's self-developed EC technology has overcome critical challenges and scaled into mass production, powering flagship models from BYD, NIO, Zeekr, and Avatr. With Audi now embracing the technology, EC dimming has entered the
More news about: Ambilight
Sep 18, 2025, 11:18 ET 奧迪首發 E5 Sportback，搭載 Ambilight 電致變色智慧調光天幕
這款 EC 天幕面積達 2.002 平方米，支援五檔亮度調節，能夠根據需求提供個人化的光線環境。其阻隔 99.99% 紫外線及 99.5% 陽光，不僅大幅提升乘客的舒適與豪華體驗，更有效改善座艙隔熱效率，進一步延長純電車型的續航表現。 EC 調光技術最早於 2005 年應用於 Ferrari Superamerica 限量版敞篷跑車，曾被視為小眾創新。隨著新能源汽車在中國於 2017 年快速發展，Ambilight 自主研發的 EC 技術突破長期技術瓶頸，達到車規級標準並實現量產。此後，包括比亞迪、蔚來、極氪、阿維塔在內的領先新能源品牌，均已在旗艦車型中搭載
More news about: Ambilight
Sep 18, 2025, 09:00 ET Castleforge and Conversant Capital Partner to Invest in Central London Office Assets
the £90 million recapitalization of 55 Mark Lane, a 162,000 square foot multi-let office asset in the City of London's EC3 insurance district. Proceeds will refinance the existing mortgage and fund a capital improvement plan. Castleforge will serve as lender, asset manager,
More news about: Castleforge and Conversant Capital
Sep 18, 2025, 09:00 ET New Research Strengthens Evidence of Cranberry Health Benefits
1. Calvano A, Izuora K, Oh EC, Ebersole JL, Lyons TJ, Basu A. Dietary berries, insulin resistance and type 2 diabetes: an overview of human feeding trials. Food Funct. 2019 Oct 16;10(10):6227-6243.
More news about: The Cranberry Institute
Sep 17, 2025, 08:00 ET Study Published in the Journal Infection Demonstrates Clinical Utility of SeptiCyte® RAPID to Diagnose Sepsis in Critically Ill Patients with Hospital Acquired Infections
SeptiCyte® RAPID is CE Marked as a near-patient sample-to-answer test in European Union (EU) member countries and those harmonized with the EU IVD Directive (98/79/EC). As of November 2021, SeptiCyte® RAPID has been FDA cleared for use in hospitalized patients suspected of sepsis. About Immunexpress
More news about: Immunexpress, Inc.